I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Most patients awaiting elective surgery experience the preoperative anxiety. Anxiety influences patient\'s subjective perceptions,\[[@ref1]\] and preoperative anxiety is associated with higher level of postoperative pain.\[[@ref2][@ref3][@ref4]\] Although the use of preoperative benzodiazepines is the most common practice to decrease preoperative anxiety, they do not have a positive effect on the postoperative outcome.\[[@ref5][@ref6]\] Recently, an increasing emphasis has been placed on the use of nonopioid analgesic drugs as part of a multimodal regimen for preventing pain in the perioperative period.\[[@ref7][@ref8][@ref9]\] Laparoscopic cholecystectomy has now replaced open cholecystectomy as the first choice of treatment for gallstones and inflammation of the gall bladder unless there are contraindications to the laparoscopic approach. Further laparoscopy results in stress hormone responses (cortisol, epinephrine, and norepinephrine), especially with Co~2~ pneumoperitoneum.\[[@ref10]\] Manipulation of airway, particularly during laryngoscopy and endotracheal intubation is associated with sympathetic nervous system stimulation and catecholamine release. This can cause serious complications in patients with underlying abnormalities such as coronary artery disease,\[[@ref11]\] reactive airways,\[[@ref12]\] or intracranial neuropathology.\[[@ref13]\] Both sympathetic and parasympathetic nervous system mediate cardiovascular responses to laryngoscopy and endotracheal intubation.\[[@ref14]\] Various anesthetic drugs and techniques have been described to control the hemodynamic response to the laryngoscopy and intubation, such as omitting cholinergic medications,\[[@ref15]\] deepening of anesthesia,\[[@ref16]\] pretreatment with nitroglycerine,\[[@ref17]\] administration of beta-blockers,\[[@ref18]\] calcium channel blockers,\[[@ref19]\] gabapentin,\[[@ref20]\] clonidine,\[[@ref21]\] and opioids such as fentanyl\[[@ref10]\] and remifentanil.\[[@ref22]\] Gabapentinoids (gabapentin and pregabalin) are the second generation of anticonvulsants that are effective in treatment of chronic neuropathic pain.\[[@ref23][@ref24]\] Pregabalin is a structural and functional analog of gabapentin and effective in the treatment of nociceptive inflammatory pain that is resistant to gabapentin. Both drugs bind to the α~2~-δ subunit of voltage-sensitive Ca^++^ channels, which sustain the enhanced release of pain transmitters at the synapses between primary afferent fibers and second-order sensory neurons under the conditions of chronic pain. However, a growing body of evidence suggests that perioperative administration is efficacious for the postoperative analgesia, preoperative anxiolysis, attenuation of the hemodynamic response to laryngoscopy and intubation and preventing chronic postsurgical pain, postoperative nausea, vomiting, and delirium.\[[@ref24]\] Only minimal evidence are available in our literature related to the attenuation of anxiety and cardiovascular properties of pregabalin in patients undergoing laparoscopic surgery. Hence, the present study was designed to evaluate the effects of oral pregabalin on anxiolysis and attenuation of stress response to laryngoscopy and endotracheal intubation.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

With approval of the Ethics Committee and informed consent of the patients, a randomized double-blind placebo-controlled study was conducted in the Department of Anesthesia, Uttar Pradesh University of Medical sciences Saifai, U. P., India, from January 2018 to December 2018. A total 60 patients of either sex and ASA physical status classification I and II, aged 18--65 years scheduled to undergo laparoscopic cholecystectomy under general anesthesia were enrolled in the study. Patients with ASA physical status classification III and IV, anticipated difficult intubation, multiple intubation (\>1) attempts at laryngoscopy, severe renal or hepatic disease, allergic, chronic hypertension, ischemic heart disease, left ventricular failure, major cardiac disorders, and obesity were excluded from the study. Patients were randomly allocated in two groups of 30 each using sealed opaque envelopes. After thorough preanesthetic evaluation, patients were randomly allocated and provided either envelope containing formulations by another staff nurse in the preoperative room 60 min before surgery. Group A received oral placebo in the form of oral multivitamin capsules, and Group B received oral pregabalin 150 mg.

On arrival in the operating room, 18G intravenous (IV) cannula was inserted in a peripheral vein, and Ringer\'s lactate solution was started at 6 mL/kg. A uniform anesthetic technique was used in all groups. After 3 min of preoxygenation, anesthesia was induced with IV thiopentone 5 mg/kg; IV succinylcholine 1.5 mg/kg to facilitate endotracheal intubation. The duration of laryngoscopy and intubation was limited to \<15 s for all patients. Monitoring of vitals was done by an anesthetist, who was blinded to the drug used in each group. Heart rate (bpm) and noninvasive systolic blood pressure (mmHg), diastolic blood pressure (mmHg), and mean arterial pressure (MAP) (mmHg) were recorded preoperatively (baseline), 60 min after administration of study drug, during laryngoscopy and intubation, and at 2, 4, 6, 8, and 10 min after intubation, after extubation and in the postoperative room. Following endotracheal intubation, a nasogastric tube (14 F) was placed. Maintenance of anesthesia was carried out using 67% N~2~0 in 33% O~2~ and halothane 0.5% using controlled ventilation. Neuromuscular blockade was achieved using vecuronium 0.08--0.12 mg/kg. Intraoperative analgesia was provided with 1--1.5 μg/kg fentanyl. At the end of surgery, residual neuromuscular blockade was reversed with neostigmine 0.05 mg/kg and glycopyrrolate 0.01 mg/kg intravenously.

Statistical analysis {#sec2-1}
--------------------

The sample size was calculated using the formula:

(*n* = \[z~(1-α/2)~\]^2^ × SD^2^/d^2^)

Where

z~(1-α/2)~= standard normal deviate for 95% confidence = 1.96

SD = Standard deviation of MAP = 14 mmHg

d = precision = 5%

*n* = 1.96^2^ × 14^2^/5^2^

*n* = 30

The sample size obtained is 30 patients in each group.

At the end of the study, results were represented as (mean ± SD) and percentage changes. The statistical analysis of quantitative data (mean ± SD) between the groups was performed using the Student\'s "t"-test. The statistical analysis of qualitative data between the groups was performed using the Chi-square test. A value of *P* \< 0.05 was considered to be statistically significant. All the analysis was performed using SPSS statistical package version 20.0 (IBM, Armonk, NY).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 60 patients were recruited for the study, and none were excluded as shown in consort chart \[[Chart 1](#F1){ref-type="fig"}\]. Both groups were comparable in terms of age, weight, sex, duration of surgery, ASA physical status classification \[[Table 1](#T1){ref-type="table"}\]. [Table 2](#T2){ref-type="table"} shows intergroup comparison of mean VAS score with respect to time whereas [Table 3](#T3){ref-type="table"} shows intragroup comparisons of VAS score in both the groups. Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}, [Figure 1](#F2){ref-type="fig"} shows the comparison of change in heart rate across time periods. Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}, [Figure 2](#F3){ref-type="fig"} shows the comparison of change in systolic blood pressure across time periods. Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}, [Figure 3](#F4){ref-type="fig"} shows the comparison of change in diastolic blood pressure across time periods. Tables [10](#T10){ref-type="table"} and [11](#T11){ref-type="table"}, [Figure 4](#F5){ref-type="fig"} shows the comparison of change in mean arterial pressure across time periods. Mean VAS score and hemodynamic parameters were found significant in pregabalin group compared to placebo group.

![Consort Flow Diagram. Group A=Placebo; Group B=Pregabalin](AER-13-97-g001){#F1}

###### 

Distribution of demographic data among the studied groups

  Parameters                  Mean±SD     *P*         
  --------------------------- ----------- ----------- ------
  Age (years)                 36.3±11.9   40.9±12.2   0.14
  Sex (%)                                             
   Male                       15 (50)     15 (50)     1.00
   Female                     15 (50)     15 (50)     
  Weight (kg)                 57.3±6.5    59.9±4.9    0.08
  Duration of surgery (min)   60.6±4.5    62.6±5.2    0.12
  ASA grade (%)                                       
   I                          8 (53)      7 (47)      1.00
   II                         7 (47)      8 (53)      

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. SD=Standard deviation, ASA=American Society of Anesthesiologists

###### 

Mean visual analog scale anxiety score in the studied groups

                                            Mean±SD     *P*         
  ----------------------------------------- ----------- ----------- ---------
  Before drug administration (BL)           68.3±14.2   66.6±17.6   0.89
  60 min after giving drug (preinduction)   58.6±14.4   49.3±14.1   \<0.001

SD=Standard deviation, *P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. SD=Standard deviation, BL=Baseline

###### 

Intragroup comparison of visual analog scale anxiety scores

                            Group A (*n*=30)   Group B (*n*=30)                                         
  ------------------------- ------------------ ------------------ ---- -------- ----------- ------ ---- ------
  Before giving drug (BL)   68.3±14.2          \-                 \-   \-       66.6±17.6   \-     \-   \-
  Preinduction              58.6±14.4          9.7                14   \<0.01   49.3±14.1   17.3   26   0.01

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. BL=Baseline, SD=Standard deviation, DL=Direct laryngoscopy

###### 

Intragroup comparison of change in heart rate across time periods among the groups

  Heart rate (beats per min)         Group A (*n*=30)   Group B (*n*=30)                                        
  ---------------------------------- ------------------ ------------------ ---- -------- ---------- ----- ----- --------
  BL                                 87.3±9.8           \-                 \-   \-       89.6±5.7   \-    \-    \-
  60 min after drug administration   88.5±8.7           1.2                1    0.61     90.0±9.2   0.4   0.4   0.84
  During DL                          118.5±6.7          31.2               36   0.0001   98.4±5.8   8.8   10    0.0001
  2^nd^ min                          116.4±5.3          29.1               33   0.0001   99.0±5.6   9.4   10    0.0001
  4^th^ min                          117.8±8.4          30.5               35   0.0001   98.5±6.6   8.9   10    0.0001
  6^th^ min                          112.2±7.9          24.9               28   0.0001   97.2±8.2   7.6   8     0.0001
  8^th^ min                          110.1±8.8          22.8               26   0.0001   97.1±6.3   7.5   8     0.0001
  10^th^ min                         106.8±9.2          19.5               22   0.0001   96.3±8.4   6.7   7     0.0006

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. BL=Baseline, SD=Standard deviation, DL=Direct laryngoscopy

###### 

Intergroup comparison of change in heart rate across time periods among the studied groups

  Heart rate (beats per min)         Mean±SD     *P*          
  ---------------------------------- ----------- ------------ --------
  BL                                 87.3±9.8    89.6±5.7     0.27
  60 min after drug administration   88.5±8.7    90.0±9.2     0.51
  During DL                          118.5±6.7   98.4±5.8     0.0001
  2nd min                            116.4±5.3   99.0±5.6     0.0001
  4th min                            117.8±8.4   98.5±6.6     0.0001
  6th min                            112.2±7.9   97.2±8.2     0.0001
  8th min                            110.1±8.8   97.1±6.3     0.0001
  10th min                           106.8±9.2   96\. 3±8.4   0.0001

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. BL=Baseline, SD=Standard deviation, DL=Direct laryngoscopy

![Line diagram showing comparison of change in heart rate across time periods among the study groups](AER-13-97-g002){#F2}

###### 

Intragroup comparison of changes of mean systolic blood pressure across the time periods among the study groups

  Systolic blood pressure (mmHg)     Group A (*n*=30)   Group B (*n*=30)                                          
  ---------------------------------- ------------------ ------------------ ----- -------- ----------- ----- ----- --------
  BL                                 128.6±6.5          \-                 \-    \-       129.8±7.1   \-    \-    \-
  60 min after drug administration   130.6±5.3          2.0                1.5   0.19     130.1±6.2   0.3   0.2   0.86
  During DL                          147.2±8.4          18.6               14    0.0001   136.5±8.8   6.7   5     0.002
  2^nd^ min                          148.4±7.6          19.8               15    0.0001   136.9±9.1   7.1   5     0.001
  4^th^ min                          150.1±9.2          21.5               17    0.0001   137.5±6.7   7.7   6     0.0001
  6^th^ min                          149.3±7.5          20.7               16    0.0001   134.3±9.4   4.5   3     0.04
  8^th^ min                          146.8±7.1          18.2               14    0.0001   133.8±7.9   4.0   3     0.04
  10^th^ min                         140.0±6.2          11.4               9     0.0001   132.3±6.6   2.5   2     0.16

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. BL=Baseline, SD=Standard deviation, DL=Direct laryngoscopy

###### 

Intergroup comparison of change in systolic blood pressure across time periods among the study groups

  Systolic blood pressure (mm Hg)    Mean±SD     *P*         
  ---------------------------------- ----------- ----------- --------
  BL                                 128.6±6.5   129.8±7.1   0.50
  60 min after drug administration   130.6±5.3   130.1±6.2   0.73
  During DL                          147.2±8.4   136.5±8.8   0.0001
  2^nd^ min                          148.4±7.6   136.9±9.1   0.0001
  4^th^ min                          150.1±9.2   137.5±6.7   0.0001
  6^th^ min                          149.3±7.5   134.3±9.4   0.0001
  8^th^ min                          146.8±7.1   133.8±7.9   0.0001
  10^th^ min                         140.0±6.2   132.3±6.6   0.0001

*P*\>0.05=Not significant, *P*\<0.05=Significant; *P*\<0.001=Highly significant. BL=Baseline, SD=Standard deviation, DL=Direct laryngoscopy

![Line diagram showing comparison of change in systolic blood pressure across time periods among the study groups](AER-13-97-g003){#F3}

###### 

Intragroup comparison of change in diastolic blood pressure across time periods among the study groups

  Diastolic blood pressure (mmHg)    Group A (*n*=30)   Group B (*n*=30)                                        
  ---------------------------------- ------------------ ------------------ ---- -------- ---------- ----- ----- -------
  BL                                 84.6±6.0           \-                 \-   \-       85.2±5.3   \-    \-    \-
  60 min after drug administration   86.3±6.9           1.7                2    0.31     85.3±5.5   0.1   0.1   0.94
  During DL                          98.4±7.9           13.8               16   0.0001   89.7±7.7   4.5   5     0.01
  2^nd^ min                          98.6±7.2           14.0               16   0.0001   89.5±6.8   4.3   5     0.008
  4^th^ min                          99.0±8.5           14.4               17   0.0001   89.5±7.2   4.3   5     0.01
  6^th^ min                          97.6±6.8           13.0               15   0.0001   89.2±7.5   3.8   4     0.02
  8^th^ min                          97.2±7.2           12.6               15   0.0001   89.0±8.3   3.6   4     0.04
  10^th^ min                         96.5±6.3           11.9               14   0.0001   87.6±7.8   2.4   3     0.16

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. SD=Standard deviation, DL=Direct laryngoscopy, BL=Baseline

###### 

Intergroup comparison of change in diastolic blood pressure across time periods among the study groups

  Diastolic blood pressure (mmHg)    Mean±SD    *P*        
  ---------------------------------- ---------- ---------- --------
  BL                                 84.6±6.0   85.2±5.3   0.68
  60 min after drug administration   86.3±6.9   85.3±5.5   0.53
  During DL                          98.4±7.9   89.7±7.7   0.0001
  2^nd^ min                          98.6±7.2   89.5±6.8   0.0001
  4^th^ min                          99.0±8.5   89.5±7.2   0.0001
  6^th^ min                          97.6±6.8   89.2±7.5   0.0001
  8^th^ min                          97.2±7.2   89.0±8.3   0.0001
  10^th^ min                         96.5±6.3   87.6±7.8   0.0001

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. SD=Standard deviation, DL=Direct laryngoscopy, BL=Baseline

![Line diagram showing comparison of change in diastolic blood pressure across time periods among the groups](AER-13-97-g004){#F4}

###### 

Intragroup comparison of change in mean arterial pressure across time periods among the groups

  Mean arterial pressure (mmHg)      Group A (*n*=30)   Group B (*n*=30)                                          
  ---------------------------------- ------------------ ------------------ ---- -------- ----------- ------ ----- --------
  BL                                 97.3±9.1           \-                 \-   \-       99.2±5.6    \-     \-    \-
  60 min after drug administration   98.6±7.2           1.3                1    0.54     99.3±8.1    0.1    0.1   0.95
  During DL                          119.4±9.8          22.1               23   0.0001   108.3±6.3   9.1    9     0.0001
  2^nd^ min                          120.5±9.6          23.2               24   0.0001   110.5±6.8   11.3   11    0.0001
  4^th^ min                          120.2±8.9          22.9               23   0.0001   110.8±6.5   11.6   12    0.0001
  6^th^ min                          120.2±7.6          22.9               23   0.0001   106.7±7.6   7.5    7     0.0001
  8^th^ min                          118.3±7.9          20.7               21   0.0001   105.5±7.5   6.3    6     0.0005
  10^th^ min                         115.8±8.2          18.5               19   0.0001   103.8±8.2   4.3    4     0.01

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. SD=Standard deviation, DL=Direct laryngoscopy, BL=Baseline

###### 

Intergroup comparison of changes in mean arterial pressure across time periods among the study groups

  Mean arterial pressure (mmHg)      Mean±SD     *P*         
  ---------------------------------- ----------- ----------- --------
  BL                                 97.3±9.1    99.2±5.6    0.33
  60 min after drug administration   98.6±7.2    99.3±8.1    0.72
  During DL                          119.4±9.8   108.3±6.3   0.0001
  2^nd^ min                          120.5±9.6   110.5±6.8   0.0001
  4^th^ min                          120.2±8.9   110.8±6.5   0.0001
  6^th^ min                          120.2±7.6   106.7±7.6   0.0001
  8^th^ min                          118.3±7.9   105.5±7.5   0.0001
  10^th^ min                         115.8±8.2   103.8±8.2   0.0001

*P*\>0.05=Not significant, *P*\<0.05=Significant, *P*\<0.001=Highly significant. SD=Standard deviation, DL=Direct laryngoscopy, BL=Baseline

![Line diagram showing comparison of changes in mean arterial pressure across time periods among the study groups](AER-13-97-g005){#F5}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The augmented cardiovascular reflexes in the form of tachycardia and hypertension brought about by the noxious stimulus of laryngoscopy and intubation can prove to be detrimental for patients with cardiovascular and cerebrovascular diseases.\[[@ref25]\] For decreasing anxiety and the intubation response, use of nonopioid drugs has become a part of the multimodal regimen. Many recent studies show that drugs such as gabapentin and pregabalin are known to decrease stress response due to laryngoscopy and intubation. Pregabalin is a drug with analgesic, anticonvulsant, and anti-anxiety effects mainly used for the management of neuropathic pain, neuralgia occurring postherpes infection, and as adjuvant for the treatment of partial onset seizures. Gabapentin and pregabalin were initially developed for the treatment of epilepsy and also for the effective management of neuropathic pain. They are also used in the perioperative period to provide pain relief. Recently, these drugs are being used in the preoperative setting to decease the anxiety and blunt the cardiovascular stress response occurring to laryngoscopy and tracheal intubation but with different doses and conflicting results.\[[@ref26][@ref27][@ref28]\]

In this study, the demographic data with respect to age, sex, ASA physical status classification, and duration of surgery were comparable among all the groups \[[Table 1](#T1){ref-type="table"}\]. Several investigators have used different scales for measuring preoperative anxiety, i.e., state-trait anxiety inventory,\[[@ref29]\] visual analog scale (VAS),\[[@ref29]\] and 5-Point scale. We choose VAS scale because it is easy to assess and reliable. Recently, de-Paris *et al*. demonstrated that gabapentin attenuated anxiety associated "with simulated public speaking" in volunteers.\[[@ref30]\] A study in patients with generalized anxiety disorders found that chronic use of pregabalin was significantly more effective than the benzodiazepine alprazolam in improving somatic anxiety symptoms.\[[@ref31]\] Preoperatively, we observed decrease in anxiety in the pregabalin group by 26% compared to that of the placebo group (14%). This is in contrast to the findings observed by White *et al*. where they studied 75, 150, and 300 mg of pregabalin and compared it with placebo. Anxiety levels remained unchanged in their study during the preoperative evaluation period and did not differ among all the groups.\[[@ref32]\] [Table 4](#T4){ref-type="table"} and [Figure 1](#F2){ref-type="fig"} show intragroup comparison of change in heart rate from baseline up to 10 min after tracheal intubation among the study groups. Throughout the monitoring and reporting of data, mean heart rate value rises to a maximum of 36% and 10% in the Group A and Group B, respectively, during direct laryngoscopy and intubation and found to be statistically significant (*P* = 0.0001). When Group A was compared with Group B, throughout the study period, there was a statistically significant difference in the mean heart rate value. [Table 6](#T6){ref-type="table"} and [Figure 2](#F3){ref-type="fig"} show intragroup comparison of change in systolic blood pressure from baseline up to 10 min after tracheal intubation among the study groups. In Group A, throughout the monitoring and reporting of data during direct laryngoscopy and intubation, mean systolic blood pressure value rises to 14% in Group A and 5% in Group B, respectively, and found to be statistically significant. However, the maximum increase is 17% in Group A and 6% in Group B observed 4 min after direct laryngoscopy and intubation and remained statistically significant throughout the duration of study except at 10 min in Group B.

[Table 7](#T7){ref-type="table"} shows intergroup comparison of change in systolic blood pressure between Group A and Group B and found to be statistically significant throughout the study period. [Table 10](#T10){ref-type="table"} and [Figure 4](#F5){ref-type="fig"} show intragroup comparison of change in MAP from baseline up to 10 min after tracheal intubation among the groups. In Group A, throughout the monitoring and reporting data, MAP value rises to a maximum of 24%, 2 min after direct laryngoscopy and intubation which was statistically significant, whereas in Group B, MAP value rises to a maximum of 12%, 4 min after laryngoscopy and intubation which was statistically significant. [Table 11](#T11){ref-type="table"} shows intergroup comparison of changes in MAP across time periods among the groups and found a statistically significant difference in MAP value between the groups. This is in consistent to the study done by Chakraborty *et al*.,\[[@ref33]\] who concluded that premedication with 150 mg of oral pregabalin safely attenuates hemodynamic response to laryngoscopy and intubation. Sundar *et al*.\[[@ref34]\] conducted a study to see the effects of preemptive pregabalin on attenuation of stress response to endotracheal intubation and opioid-sparing effect in patients undergoing off-pump coronary artery bypass graft and concluded that pregabalin 150 mg succeeded in suppressing reflex tachycardia related to laryngoscopy and intubation. In another similar study done by Singh *et al*.\[[@ref35]\] to evaluate the effects of oral pregabalin as premedication for attenuation of pressor response during laryngoscopy and endotracheal intubation and found that magnitude of rise in heart rate is lower and it is falling to less than the basal value at 10 min in the pregabalin group, but in the control group, it has not reached the basal value even by 10 min following laryngoscopy and intubation. Saxena *et al*.\[[@ref36]\] conducted a study to see the effect of pregabalin premedication on laryngoscopic response and intraoperative hemodynamic variables in laparoscopic cholecystectomy and observed that 150 mg and 300 mg pregabalin were equally effective in attenuating the increase in heart rate during laryngoscopy and intubation. Raichurkar *et al*.\[[@ref37]\] conducted a comparative study on oral pregabalin and clonidine for attenuation of hemodynamic responses to laryngoscopy and tracheal intubation and concluded that pregabalin and clonidine successfully attenuated the hemodynamic response to laryngoscopy and tracheal intubation, but pregabalin better attenuates pressor response, and clonidine better attenuates tachycardia response. Eren *et al*.\[[@ref38]\] used pregabalin to know its effectiveness in blunting the hemodynamic response to intubation in lumbar surgeries among 50 patients undergoing elective lumbar disc surgery, and found MAP values are significantly low in the pregabalin 150 group compared to the placebo group (108.3 ± 6.3 vs. 119.4 ± 9.8, *P* = 0.0001) during laryngoscopy and intubation even up to 10^th^ min, i.e., a rise of mean MAP from baseline was 9% in pregabalin 150 mg as compared to 23% in the placebo group. Rastogi *et al*.\[[@ref39]\] conducted prospective randomized controlled study using two various doses of pregabalin to find out the clinically effective and safe dose during airway manipulation to maintain the hemodynamics and observed the attenuation of MAP in the premedicated group was statistically significant, i.e., in pregabalin 75 mg group (97.80 ± 2.52 vs. 110.70 ± 4.94, *P* = 0.001) and in pregabalin 150 mg group (92.06 ± 3.37 vs. 110.70 ± 4.94, *P* = 0.001) to as compared with control group, in dose-related fashion.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

From the present study, we conclude that pregabalin 150 mg seems to be an effective and safe drug for anxiolysis, analgesia, and hemodynamic stability during laryngoscopy and intubation and can be useful for patients with comorbid conditions preoperatively.
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